Pub Date : 2026-03-19DOI: 10.1186/s13550-026-01413-z
Xingyu Mu, Meng Li, Jie Qin, Jinquan Huang, Longhao Song, Wenguo Sun, Wei Fu
Background: Although [¹⁸F]PSMA-1007 enables sensitive detection in prostate cancer, heterogeneity in PSMA expression and variable physiologic uptake can limit performance, whereas [¹⁸F]FAPI-42, targeting fibroblast activation protein in tumor stroma and typically exhibiting low background, may improve conspicuity in regions affected by physiologic PSMA activity and in phenotypes with reduced PSMA expression. This study aimed to compare [¹⁸F]FAPI-42 and [¹⁸F]PSMA-1007 PET/CT in patients with prostate cancer, and assess lesion detection rates and uptake on [¹⁸F]FAPI-42 PET/CT across various disease stages.
Results: Of 759 lesions from 55 patients, 187 were PSMA-positive only, 72 were FAPI-positive only, and 500 were positive on both tracers. [¹⁸F]PSMA-1007 detected more lesions in newly diagnosed (233 vs. 181, P = 0.0001), biochemical recurrence (BCR) (67 vs. 56, P = 0.04), and castration-resistant prostate cancer(CRPC) (385 vs. 333, P < 0.0001) groups. [¹⁸F]PSMA-1007 also demonstrated higher SUVmax and TBRblood than [¹⁸F]FAPI-42 PET/CT for primary/recurrent tumors (SUVmax 15.5 ± 16.8 vs. 4.2 ± 2.2; TBRblood 13.5 ± 14.0 vs. 3.5 ± 2.9), lymph node (SUVmax 14.9 ± 15.3 vs. 3.8 ± 2.7; TBRblood 12.8 ± 12.1 vs. 3.5 ± 2.9), bone (SUVmax 11.9 ± 9.4 vs. 6.8 ± 3.5; TBRblood 13.1 ± 12.1 vs. 6.3 ± 3.5), and visceral metastases (SUVmax 14.6 ± 9.4 vs. 7.8 ± 4.6; TBRblood 22.8 ± 12.3 vs. 6.9 ± 6.2). Among disease stages, lesion detection rates on [¹⁸F]FAPI-42 were higher in CRPC (84.5%) and BCR (75.7%) than in newly diagnosed cases (62.6%; P < 0.0001 and P = 0.04, respectively). SUVmax of lesion on [¹⁸F]FAPI-42 PET/CT were highest in CRPC (6.6 ± 3.9), followed by BCR (5.9 ± 3.7), and newly diagnosed disease (4.3 ± 2.5; P < 0.005). In 3 of 5 patients with discordant findings favoring [¹⁸F]FAPI-42, clinical management was altered.
Conclusion: While [¹⁸F]PSMA 1007 PET/CT remains superior for overall lesion detection, [¹⁸F]FAPI 42 PET/CT may provide complementary value in selected scenarios, particularly in subsets with reduced PSMA expression.
Trial registration: Chinese Clinical Trial Registry, ChiCTR2200063441. Registered 06 September 2022, https//www.chictr.org.cn/bin/project/edit? pid=149,714.
背景：虽然[¹⁸F]PSMA-1007能够灵敏地检测前列腺癌，但PSMA表达的异质性和可变的生理摄取可能会限制检测效果，而[¹⁸F]FAPI-42靶向肿瘤基质中的成纤维细胞激活蛋白，通常具有低背景，可能会改善受PSMA生理性活性影响的区域和PSMA表达减少的表型的显著性。本研究旨在比较[¹⁸F]FAPI-42和[¹⁸F]PSMA-1007 PET/CT在前列腺癌患者中的表现，并评估[¹⁸F]FAPI-42 PET/CT在不同疾病阶段的病变检出率和摄取情况。结果：55例患者的759个病变中，187个仅为psma阳性，72个仅为fapi阳性，500个两种示踪剂均阳性。[¹⁸F) - 1007检测到更多的病变psma新诊断(233与181,P = 0.0001),生化复发(BCR)(67和56,P = 0.04),和castration-resistant前列腺癌(CRPC)(385年和333年,P马克斯和TBRblood比[¹⁸F] FAPI-42 PET / CT主要/复发性肿瘤(SUVmax 15.5±16.8和4.2±2.2;TBRblood 13.5±14.0和3.5±2.9),淋巴结(SUVmax 14.9±15.3和3.8±2.7;TBRblood 12.8±12.1和3.5±2.9),骨(SUVmax 11.9±9.4和6.8±3.5;TBRblood 13.1±12.1 vs. 6.3±3.5)和内脏转移（SUVmax 14.6±9.4 vs. 7.8±4.6;TBRblood 22.8±12.3 vs. 6.9±6.2）。在不同的疾病分期中，[¹⁸F]FAPI-42的病变检出率在CRPC（84.5%）和BCR（75.7%）高于新诊断病例（62.6%）；[¹⁸F]FAPI-42 PET/CT上病变的最大P值在CRPC（6.6±3.9）最高，其次是BCR(5.9±3.7)，新诊断病例（4.3±2.5）；结论：虽然[¹⁸F]PSMA 1007 PET/CT在整体病变检测方面仍具有优势，但[¹⁸F]FAPI 42 PET/CT在某些情况下可能具有补充价值，特别是在PSMA表达减少的亚群中。试验注册：中国临床试验注册中心，ChiCTR2200063441。注册于2022年9月6日，https//www.chictr.org.cn/bin/project/edit？pid = 149714。
{"title":"Comparative evaluation of [¹⁸F]FAPI-42 and [¹⁸F]PSMA-1007 PET/CT for lesion detection and uptake in prostate cancer across disease stages.","authors":"Xingyu Mu, Meng Li, Jie Qin, Jinquan Huang, Longhao Song, Wenguo Sun, Wei Fu","doi":"10.1186/s13550-026-01413-z","DOIUrl":"https://doi.org/10.1186/s13550-026-01413-z","url":null,"abstract":"<p><strong>Background: </strong>Although [¹⁸F]PSMA-1007 enables sensitive detection in prostate cancer, heterogeneity in PSMA expression and variable physiologic uptake can limit performance, whereas [¹⁸F]FAPI-42, targeting fibroblast activation protein in tumor stroma and typically exhibiting low background, may improve conspicuity in regions affected by physiologic PSMA activity and in phenotypes with reduced PSMA expression. This study aimed to compare [¹⁸F]FAPI-42 and [¹⁸F]PSMA-1007 PET/CT in patients with prostate cancer, and assess lesion detection rates and uptake on [¹⁸F]FAPI-42 PET/CT across various disease stages.</p><p><strong>Results: </strong>Of 759 lesions from 55 patients, 187 were PSMA-positive only, 72 were FAPI-positive only, and 500 were positive on both tracers. [¹⁸F]PSMA-1007 detected more lesions in newly diagnosed (233 vs. 181, P = 0.0001), biochemical recurrence (BCR) (67 vs. 56, P = 0.04), and castration-resistant prostate cancer(CRPC) (385 vs. 333, P < 0.0001) groups. [¹⁸F]PSMA-1007 also demonstrated higher SUV<sub>max</sub> and TBR<sub>blood</sub> than [¹⁸F]FAPI-42 PET/CT for primary/recurrent tumors (SUV<sub>max</sub> 15.5 ± 16.8 vs. 4.2 ± 2.2; TBR<sub>blood</sub> 13.5 ± 14.0 vs. 3.5 ± 2.9), lymph node (SUV<sub>max</sub> 14.9 ± 15.3 vs. 3.8 ± 2.7; TBR<sub>blood</sub> 12.8 ± 12.1 vs. 3.5 ± 2.9), bone (SUV<sub>max</sub> 11.9 ± 9.4 vs. 6.8 ± 3.5; TBR<sub>blood</sub> 13.1 ± 12.1 vs. 6.3 ± 3.5), and visceral metastases (SUV<sub>max</sub> 14.6 ± 9.4 vs. 7.8 ± 4.6; TBR<sub>blood</sub> 22.8 ± 12.3 vs. 6.9 ± 6.2). Among disease stages, lesion detection rates on [¹⁸F]FAPI-42 were higher in CRPC (84.5%) and BCR (75.7%) than in newly diagnosed cases (62.6%; P < 0.0001 and P = 0.04, respectively). SUV<sub>max</sub> of lesion on [¹⁸F]FAPI-42 PET/CT were highest in CRPC (6.6 ± 3.9), followed by BCR (5.9 ± 3.7), and newly diagnosed disease (4.3 ± 2.5; P < 0.005). In 3 of 5 patients with discordant findings favoring [¹⁸F]FAPI-42, clinical management was altered.</p><p><strong>Conclusion: </strong>While [¹⁸F]PSMA 1007 PET/CT remains superior for overall lesion detection, [¹⁸F]FAPI 42 PET/CT may provide complementary value in selected scenarios, particularly in subsets with reduced PSMA expression.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry, ChiCTR2200063441. Registered 06 September 2022, https//www.chictr.org.cn/bin/project/edit? pid=149,714.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-16DOI: 10.1186/s13550-026-01408-w
Niklas Ebert, Florian Rosar, Caroline Burgard, Mark Bartholomä, Stephan Maus, Connor Hein, Arne Blickle, Samer Ezziddin, Fadi Khreish
{"title":"Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience.","authors":"Niklas Ebert, Florian Rosar, Caroline Burgard, Mark Bartholomä, Stephan Maus, Connor Hein, Arne Blickle, Samer Ezziddin, Fadi Khreish","doi":"10.1186/s13550-026-01408-w","DOIUrl":"https://doi.org/10.1186/s13550-026-01408-w","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147466538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-14DOI: 10.1186/s13550-026-01396-x
Emirhan Harbi, Gokce Belge Bilgin, Louise Emmett, Ayse T Kendi, Jacob J Orme, Miguel Muniz, Daniel S Childs, Fabrice Lucien, Aadel A Chaudhuri, Oliver Sartor
{"title":"Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting.","authors":"Emirhan Harbi, Gokce Belge Bilgin, Louise Emmett, Ayse T Kendi, Jacob J Orme, Miguel Muniz, Daniel S Childs, Fabrice Lucien, Aadel A Chaudhuri, Oliver Sartor","doi":"10.1186/s13550-026-01396-x","DOIUrl":"https://doi.org/10.1186/s13550-026-01396-x","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-13DOI: 10.1186/s13550-026-01390-3
Alina Toni Küper, Sofia Carrilho Vaz, Kim Magaly Pabst, Ieva Ciuciulkaite, Ilektra Antonia Mavroeidi, Rainer Hamacher, Anja Welt, Noah Hammersen, Pedro Fragoso Costa, Loic Djaileb, Robert Seifert, Lale Umutlu, Martin Schuler, Ken Herrmann, Wolfgang Peter Fendler, Sherko Kümmel, David Kersting
Background: Fibroblast activation protein (FAP)-targeted tracers have emerged as promising agents for breast cancer imaging, with recent studies demonstrating PET performance comparable to or surpassing, that of [18F]FDG. Nevertheless, data comparing [68Ga]Ga-FAPI-46 and [18F]FDG uptake in hormone receptor and/or HER2-positive breast cancer (luminal-like vs HER2-positive) remain scarce. Aim of this study was to investigate the diagnostic performance of [68Ga]Ga-FAPI-46 versus [18F]FDG PET/CT in patients with hormone-receptor and/or HER2-positive breast cancer, and to evaluate the uptake of both tracers stratified by molecular subtypes (luminal-like vs HER2-positive). A sub-analysis of a prospective observational trial (NCT04571086) was conducted. Patients with histologically confirmed, hormone receptor- and/or HER2-positive breast cancer who underwent whole-body [68Ga]Ga-FAPI-46 and [18F]FDG PET/CT in the same week for initial staging or follow-up were included. [68Ga]Ga-FAPI-46 or [18F]FDG PET-positive lesions were defined as visually increased lesion uptake compared to adjacent organ background. Semi-automatic segmentation was performed to determine SUVmax, SUVpeak, TLRpeak, total number of lesions, total tumour volume, and total tumour SUV mean. Data were compared between molecular subtypes (luminal-like vs HER2-positive).
Results: Thirteen patients were included. Overall, the detection performance was comparable between [68Ga]Ga-FAPI-46 and [18F]FDG PET. The semi-quantitative analysis showed comparable mean uptake values in breast cancer lesions on [68Ga]Ga-FAPI-46 and [18F]FDG PET/CT (SUVmax: 13.4 vs. 12.9; TLRpeak: 5.6 vs. 4.5) and revealed no significant differences in the median lesion count (4.5 vs. 5), mean total tumour volume (71.5 vs. 73.2 mL), or mean total tumour SUVmean (5.4 vs. 5.4). No substantial differences between molecular subtypes (luminal-like vs. HER2-positive) were observed.
Conclusion: In this small exploratory cohort, comparable uptake patterns in [68Ga]Ga-FAPI-46- and [18F]FDG-positive breast cancer lesions were observed across subtypes, underscoring the potential of [68Ga]Ga-FAPI-46 as a versatile imaging tool. Future studies in larger cohorts are warranted to explore the potential of FAP-targeted theranostics in different breast cancer subtypes.
Trial registration: 68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial, NCT04571086, 09-15-2020, https://clinicaltrials.gov/study/NCT04571086.
背景：纤维母细胞活化蛋白（FAP）靶向示踪剂已成为乳腺癌成像的有希望的药物，最近的研究表明PET的性能与[18F]FDG相当或超过FDG。然而，比较[68Ga]Ga-FAPI-46和[18F]FDG在激素受体和/或her2阳性乳腺癌（发光样与her2阳性）中的摄取的数据仍然很少。本研究的目的是探讨[68Ga]Ga-FAPI-46与[18F]FDG PET/CT在激素受体和/或her2阳性乳腺癌患者中的诊断性能，并评估两种示踪剂按分子亚型（发光样与her2阳性）分层的摄取情况。对一项前瞻性观察性试验（NCT04571086）进行亚分析。组织学证实的激素受体和/或her2阳性乳腺癌患者在同一周内接受了全身[68Ga]Ga-FAPI-46和[18F]FDG PET/CT进行初始分期或随访。[68Ga]Ga-FAPI-46或[18F]FDG pet阳性病变定义为与邻近器官背景相比，视觉上病变摄取增加。进行半自动分割，确定SUVmax、SUVpeak、TLRpeak、病灶总数、肿瘤总体积、肿瘤总SUV均值。比较分子亚型之间的数据（发光样与her2阳性）。结果：纳入13例患者。总体而言，[68Ga]Ga-FAPI-46和[18F]FDG PET的检测性能相当。半定量分析显示，乳腺癌病变在[68Ga]Ga-FAPI-46和[18F]FDG PET/CT上的平均摄取值相当（SUVmax: 13.4 vs. 12.9; TLRpeak: 5.6 vs. 4.5），在中位病变计数（4.5 vs. 5）、平均肿瘤总体积（71.5 vs. 73.2 mL）或平均肿瘤总体积（5.4 vs. 5.4）方面无显著差异。分子亚型（发光样与her2阳性）之间没有观察到实质性差异。结论：在这个小型探索性队列中，在不同亚型的乳腺癌病变中观察到[68Ga]Ga-FAPI-46和[18F] fdg阳性的摄取模式相似，强调了[68Ga]Ga-FAPI-46作为一种多功能成像工具的潜力。未来在更大规模的研究中，有必要探索fap靶向治疗不同乳腺癌亚型的潜力。试验注册：68-Ga-FAPI-PET用于肿瘤检测：一项前瞻性观察试验，NCT04571086, 09-15-2020, https://clinicaltrials.gov/study/NCT04571086。
{"title":"Comparison between [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer.","authors":"Alina Toni Küper, Sofia Carrilho Vaz, Kim Magaly Pabst, Ieva Ciuciulkaite, Ilektra Antonia Mavroeidi, Rainer Hamacher, Anja Welt, Noah Hammersen, Pedro Fragoso Costa, Loic Djaileb, Robert Seifert, Lale Umutlu, Martin Schuler, Ken Herrmann, Wolfgang Peter Fendler, Sherko Kümmel, David Kersting","doi":"10.1186/s13550-026-01390-3","DOIUrl":"https://doi.org/10.1186/s13550-026-01390-3","url":null,"abstract":"<p><strong>Background: </strong>Fibroblast activation protein (FAP)-targeted tracers have emerged as promising agents for breast cancer imaging, with recent studies demonstrating PET performance comparable to or surpassing, that of [<sup>18</sup>F]FDG. Nevertheless, data comparing [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG uptake in hormone receptor and/or HER2-positive breast cancer (luminal-like vs HER2-positive) remain scarce. Aim of this study was to investigate the diagnostic performance of [<sup>68</sup>Ga]Ga-FAPI-46 versus [<sup>18</sup>F]FDG PET/CT in patients with hormone-receptor and/or HER2-positive breast cancer, and to evaluate the uptake of both tracers stratified by molecular subtypes (luminal-like vs HER2-positive). A sub-analysis of a prospective observational trial (NCT04571086) was conducted. Patients with histologically confirmed, hormone receptor- and/or HER2-positive breast cancer who underwent whole-body [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG PET/CT in the same week for initial staging or follow-up were included. [<sup>68</sup>Ga]Ga-FAPI-46 or [<sup>18</sup>F]FDG PET-positive lesions were defined as visually increased lesion uptake compared to adjacent organ background. Semi-automatic segmentation was performed to determine SUVmax, SUVpeak, TLRpeak, total number of lesions, total tumour volume, and total tumour SUV mean. Data were compared between molecular subtypes (luminal-like vs HER2-positive).</p><p><strong>Results: </strong>Thirteen patients were included. Overall, the detection performance was comparable between [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG PET. The semi-quantitative analysis showed comparable mean uptake values in breast cancer lesions on [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG PET/CT (SUV<sub>max</sub>: 13.4 vs. 12.9; TLR<sub>peak</sub>: 5.6 vs. 4.5) and revealed no significant differences in the median lesion count (4.5 vs. 5), mean total tumour volume (71.5 vs. 73.2 mL), or mean total tumour SUV<sub>mean</sub> (5.4 vs. 5.4). No substantial differences between molecular subtypes (luminal-like vs. HER2-positive) were observed.</p><p><strong>Conclusion: </strong>In this small exploratory cohort, comparable uptake patterns in [<sup>68</sup>Ga]Ga-FAPI-46- and [<sup>18</sup>F]FDG-positive breast cancer lesions were observed across subtypes, underscoring the potential of [<sup>68</sup>Ga]Ga-FAPI-46 as a versatile imaging tool. Future studies in larger cohorts are warranted to explore the potential of FAP-targeted theranostics in different breast cancer subtypes.</p><p><strong>Trial registration: </strong>68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial, NCT04571086, 09-15-2020, https://clinicaltrials.gov/study/NCT04571086.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-13DOI: 10.1186/s13550-026-01410-2
Chloé François, Thomas Carlier, Cyrille Touzeau, Anna Janz, Constance Dubégny, Bastien Jamet, Françoise Kraeber-Bodéré, Clément Bailly, Caroline Bodet-Milin
{"title":"Optimal acquisition time of [<sup>68</sup>Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol.","authors":"Chloé François, Thomas Carlier, Cyrille Touzeau, Anna Janz, Constance Dubégny, Bastien Jamet, Françoise Kraeber-Bodéré, Clément Bailly, Caroline Bodet-Milin","doi":"10.1186/s13550-026-01410-2","DOIUrl":"https://doi.org/10.1186/s13550-026-01410-2","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147442860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-09DOI: 10.1186/s13550-026-01404-0
Marcus Hacker
{"title":"EJNMMI research: a vision for the next era of nuclear medicine.","authors":"Marcus Hacker","doi":"10.1186/s13550-026-01404-0","DOIUrl":"10.1186/s13550-026-01404-0","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"16 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-09DOI: 10.1186/s13550-026-01398-9
Christian Salomonsen, Luigi T Luppino, Fredrik Aspheim, Kristoffer Wickstrøm, Elisabeth Wetzer, Michael Kampffmeyer, Rodrigo Berzaghi, Rune Sundset, Robert Jenssen, Samuel Kuttner
{"title":"A robust and versatile deep learning model for prediction of the arterial input function in dynamic small animal [<sup>18</sup>F] FDG PET imaging.","authors":"Christian Salomonsen, Luigi T Luppino, Fredrik Aspheim, Kristoffer Wickstrøm, Elisabeth Wetzer, Michael Kampffmeyer, Rodrigo Berzaghi, Rune Sundset, Robert Jenssen, Samuel Kuttner","doi":"10.1186/s13550-026-01398-9","DOIUrl":"https://doi.org/10.1186/s13550-026-01398-9","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-09DOI: 10.1186/s13550-026-01409-9
Eman E Ahmed, Jack R Andrews, Mohamed E Ahmed, Rimki Haloi, Lauren A Rhodes, Mindie Mahon, Day A Carter, Nancy Wei, Mattew P Thorpe, Geoffrey B Johnson, Eugene D Kwon, Ayse Tuba Kendi
{"title":"Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer.","authors":"Eman E Ahmed, Jack R Andrews, Mohamed E Ahmed, Rimki Haloi, Lauren A Rhodes, Mindie Mahon, Day A Carter, Nancy Wei, Mattew P Thorpe, Geoffrey B Johnson, Eugene D Kwon, Ayse Tuba Kendi","doi":"10.1186/s13550-026-01409-9","DOIUrl":"https://doi.org/10.1186/s13550-026-01409-9","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号